The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions
Pharmaceuticals, 2021 Galcanezumab is a humanized monoclonal antibody blocking the calcitonin gene-related peptide (CGRP) pathway by targeting the CGRP. Data from four phase-3 randomized placebo-controlled clinical trials showed that galcanezumab is superior to placebo in ...
Panagiotis Gklinos, Dimos D. Mitsikostas
doaj +1 more source
Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway [PDF]
, 2023 BACKGROUND: New acute and preventive migraine medications are available, but data on current treatment patterns are limited. This study describes migraine treatment patterns among patients initiating novel acute migraine specific medications (nAMSMs ...
Bensink, Mark E +9 more
core +2 more sources
Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options : A Literature Review [PDF]
, 2023 Chronic pain conditions have a high socio-economic impact and represent a burden for patients, and their management is a challenge for healthcare professionals.
Csáti Anett +3 more
core +1 more source
11th European Headache Federation Congress jointly with 31st Congress of the Italian Society for the Study of Headaches : Rome, Italy. 01-03 December 2017 [PDF]
, 2017 . Aims of the study were explore the relationship between peripheral chromatic and central visual dysfunction evaluating also the presence of functional receptor impairment in patients with migraine, with and without aura examined ...
Brighina, F +5 more
core +1 more source
The Journal of Headache and Pain, 2018 Background Maintenance of effect following treatment with galcanezumab compared to placebo in adult patients with episodic or chronic migraine was evaluated.
Stefanie Förderreuther +4 more
doaj +1 more source
Gender aspects of CGRP in migraine [PDF]
, 2017 Background: Migraine is two to three times more prevalent in women than in men, but the mechanisms involved in this gender disparity are still poorly understood.
Labastida-Ramírez, A. (Alejandro) +3 more
core +2 more sources
The Journal of Headache and Pain, 2021 Background Patients with episodic migraine (EM) with a higher-frequency of migraine headache days (HFEM: 8–14 migraine headache days/month) have a greater disease burden and a higher risk of progressing to chronic migraine (CM) with associated acute ...
Jakub Jedynak +4 more
doaj +1 more source
Safety profile of monoclonal antibodies targeting the calcitonin gene-related peptide system in pregnancy: Updated analysis in VigiBase® [PDF]
, 2023 Background: Safety data on the use of migraine preventive monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) system in pregnancy are limited.
Bedussi, Francesca +4 more
core +1 more source
eLife, 2022 Background: Monoclonal antibodies (mAbs) against calcitonin gene-related peptides (CGRP) are novel treatments for migraine prevention. Based on a previous functional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (
Hauke Basedau +5 more
doaj +1 more source
Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience [PDF]
, 2022 Background: Migraine frequency increases after the cessation of successful preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs). In this study, we aimed to evaluate the course of migraine after treatment resumption.
Mecklenburg, Jasper +7 more
core +1 more source